Phase II Study Evaluating Postoperative Moderately Hypofractionated Intensity-Modulated Radiotherapy for Cervical Cancer After Hysterectomy

What this Trial Is About

Researchers are evaluating the safety and effectiveness of moderately hypofractionated intensity-modulated radiotherapy IMRT as a treatment for cervical cancer patients who have undergone a hysterectomy. This phase II, multicenter trial focuses on patients with specific types of cervical cancer, assessing treatment-related side effects and survival outcomes. The study aims to improve postoperative care by closely monitoring toxicities and quality of life after radiotherapy. Participants receive moderately hypofractionated IMRT, which involves 17 sessions of radiation delivered once daily at a dose of 2.5 Gy per fraction. This treatment begins within three months after radical hysterectomy with pelvic lymph node dissection. The study primarily examines acute gastrointestinal, genitourinary, and blood-related toxicities during and up to three months post-radiotherapy. Secondary assessments include longer-term side effects, quality of life questionnaires, and survival rates over two years. During the trial, participants are regularly monitored for side effects and quality of life using standardized questionnaires and clinical evaluations. Researchers collect data on disease-free survival and overall survival at two years. The monitoring includes assessments of acute toxicities within three months and late toxicities up to one year after treatment. The study lasts up to two years to ensure comprehensive safety and efficacy data are gathered.

Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer